Display options
Cite
Wang HF, Li LF, Guo SH, et al. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 2016;6:33440doi: 10.1038/srep33440.
Wang, H. F., Li, L. F., Guo, S. H., Zeng, Q. Y., Ning, F., Liu, W. L., & Zhang, G. (2016). Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Scientific reports, 633440. https://doi.org/10.1038/srep33440
Wang, Hai-Fang, et al. "Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer." Scientific reports vol. 6 (2016): 33440. doi: https://doi.org/10.1038/srep33440
Wang HF, Li LF, Guo SH, Zeng QY, Ning F, Liu WL, Zhang G. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 2016 Sep 28;6:33440. doi: 10.1038/srep33440. PMID: 27678333; PMCID: PMC5039407.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2016 Sep 28;6:33440. doi: 10.1038/srep33440.

Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer.

Scientific reports

Hai-Fang Wang, Lin-Fang Li, Song-He Guo, Qiu-Yao Zeng, Fen Ning, Wan-Li Liu, Ge Zhang

Affiliations

  1. Department of Microbial and Biochemical Pharmacy, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
  2. Department of Clinical Laboratory Medicine, Sun Yat-sen University cancer center, Guangzhou, China.
  3. Guangzhou Institute of Pediatrics, Department of Obstetrics, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.

PMID: 27678333 PMCID: PMC5039407 DOI: 10.1038/srep33440

Abstract

Fusobacterium nucleatum (F. nucleatum, Fn) is associated with the colorectal cancer (CRC). Fn-infection could induce significant levels of serum Fn-specific antibodies in human and mice. The objective of this study was to identify Fn-infection that elicit a humoral response in patients with CRC and evaluate the diagnostic performance of serum anti-Fn antibodies. In this work, we showed the mean absorbance value of anti-Fn-IgA and -IgG in the CRC group were significantly higher than those in the benign colon disease group and healthy control group (P < 0.001). The sensitivity and specificity of ELISA for the detection of anti-Fn-IgA were 36.43% and 92.71% based on the optimal cut-off. The combination of anti-Fn-IgA and carcino-embryonic antigen (CEA) was better for diagnosing CRC (Sen: 53.10%, Spe: 96.41%; AUC = 0.848). Furthermore, combining anti-Fn-IgA with CEA and carbohydrate antigen 19-9 (CA19-9) (Sen: 40.00%, Spe: 94.22%; AUC = 0.743) had the better ability to classify CRC patients with stages I-II. These results suggested that Fn-infection elicited high level of serum anti-Fn antibodies in CRC patients, and serum anti-Fn-IgA level may be a potential diagnosing biomarker for CRC. Serum anti-Fn-IgA in combination with CEA and CA19-9 increases the sensitivity of detecting early CRC.

References

  1. Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1381-90 - PubMed
  2. J Periodontal Implant Sci. 2015 Oct;45(5):178-83 - PubMed
  3. Cancer Sci. 2015 Sep;106(9):1196-201 - PubMed
  4. Pediatr Rheumatol Online J. 2016 Feb 09;14 (1):8 - PubMed
  5. Gut. 2016 Dec;65(12 ):1973-1980 - PubMed
  6. BMC Med. 2011 Dec 14;9:133 - PubMed
  7. Gut. 2017 Jan;66(1):70-78 - PubMed
  8. Clin Vaccine Immunol. 2012 Jul;19(7):1093-101 - PubMed
  9. Clin Exp Immunol. 2002 May;128(2):238-44 - PubMed
  10. Vaccine. 2009 Mar 4;27(10):1589-95 - PubMed
  11. Gastroenterology. 2008 May;134(5):1570-95 - PubMed
  12. J Clin Virol. 2010 Jan;47(1):43-8 - PubMed
  13. Genome Res. 2012 Feb;22(2):299-306 - PubMed
  14. Chest. 2003 Sep;124(3):832-3 - PubMed
  15. J Natl Cancer Inst. 2013 Dec 18;105(24):1907-11 - PubMed
  16. J Periodontal Res. 1992 Sep;27(5):511-21 - PubMed
  17. Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1091-4 - PubMed
  18. J Clin Periodontol. 1995 Nov;22(11):842-9 - PubMed
  19. Panminerva Med. 2015 Sep;57(3):127-43 - PubMed
  20. J Periodontol. 2009 Apr;80(4):634-47 - PubMed
  21. Crit Rev Oral Biol Med. 2001;12(2):179-85 - PubMed
  22. J Urban Health. 2005 Sep;82(3):510-6 - PubMed
  23. Front Microbiol. 2015 Feb 02;6:20 - PubMed
  24. Alzheimers Dement. 2012 May;8(3):196-203 - PubMed
  25. Genome Res. 2012 Feb;22(2):292-8 - PubMed
  26. PLoS One. 2015 Jun 16;10(6):e0129795 - PubMed
  27. Immunol Lett. 2014 Dec;162(2 Pt A):54-61 - PubMed
  28. Dig Endosc. 2016 Apr;28(3):243-9 - PubMed
  29. J Periodontol. 1992 Dec;63(12 Suppl):1110-6 - PubMed
  30. Cancer Res. 2014 Mar 1;74(5):1311-8 - PubMed
  31. Cancer. 2014 May 1;120(9):1353-60 - PubMed
  32. Arthritis Rheumatol. 2014 May;66(5):1090-100 - PubMed
  33. Infect Immun. 1985 May;48(2):534-9 - PubMed
  34. Clin Microbiol Rev. 1996 Jan;9(1):55-71 - PubMed
  35. J Appl Microbiol. 2001 Jan;90(1):68-72 - PubMed
  36. Trends Microbiol. 2013 Oct;21(10):506-8 - PubMed
  37. Cancer Epidemiol Biomarkers Prev. 2013 Sep;22(9):1567-76 - PubMed
  38. World J Gastroenterol. 2016 Jan 14;22(2):557-66 - PubMed
  39. Brain Behav Immun. 2014 May;38:1-12 - PubMed
  40. PLoS One. 2013;8(1):e53653 - PubMed
  41. Microb Ecol. 2013 Aug;66(2):462-70 - PubMed
  42. Br J Cancer. 2011 Jun 7;104(12):1896-905 - PubMed

Publication Types